Thyrotropin-releasing hormone in critical illness: From a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations

Critical Care Medicine

Volumn 24, Issue 4, 1996, Pages 590-595

  Van Den Berghe, Greet ^a   De Zegher, Francis ^a   Vlasselaers, Dirk ^a   Schetz, Miet ^a   Verwaest, Charles ^a   Ferdinande, Patrick ^a   Lauwers, Peter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Critical illness; Dopamine; Growth hormone; Immune function; Intensive care; Prolactin; Thyroid hormone; Thyroid stimulating hormone; Thyrotropin; Thyrotropin releasing hormone

Indexed keywords

GROWTH HORMONE; LIOTHYRONINE; PROLACTIN; PROTIRELIN; THYROTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CRITICAL ILLNESS; EUTHYROID SICK SYNDROME; GROWTH HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; IMMUNE FUNCTION TEST; INTRAVENOUS DRUG ADMINISTRATION; LIOTHYRONINE BLOOD LEVEL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; CRITICAL ILLNESS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROLACTIN; PROSPECTIVE STUDIES; THYROTROPIN-RELEASING HORMONE; TIME FACTORS; TRIIODOTHYRONINE;

EID: 0029935047     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199604000-00007     Document Type: Article

References (28)

1. Wartofski L, Burman KD: Alterations in thyroid function in patients with systemic illness: The "euthyroid sick syndrome." Endocr Rev 1982; 3:164-167
2. Docter R, Krenning EP, de Jong M, et al: The sick euthyroid syndrome: Changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol 1993; 39:499-518
3. Bacci V, Schussler GC, Kaplan TB: The relationship between serum triiodothyronine and thyrotropin during systemic illness. J Clin Endocrinol Metab 1982; 54:1229-1235
4. Utiger RD: Decreased extrathyroidal triiodothyronine production in nonthyroidal illness: Benefit or harm? Am J Med 1980; 69:807-810
5. Wehman RE, Gregerman RI, Burns WH, et al: Suppression of thyrotropin in the low-thyroxine state of severe nonthyroidal illness. N Engl J Med 1985; 312:546-552
6. Faber J, Kirkegaard C, Rasmussen B, et al: Pituitary-thyroid axis in critical illness. J Clin Endocrinol Metab 1987; 65:315-320
7. Sumita S, Ujike Y, Namiki A, et al: Suppression of the thyrotropin response to thyrotropin-releasing hormone and its association with severity of critical illness. Crit Care Med 1994; 22: 1603-1609
8. 4-syndrome. Acta Endocrinol 1982; 101: 542-549
9. Heinen E, Herrmann J, Königshausen TH, et al: Secondary hypothyroidism in severe non thyroidal illness? Horm Metab Res 1981; 13:284-288
10. Talwar KK, Sawhney RC, Rastogi GK: Serum levels of thyrotropin, thyroid hormones and their response to thyrotropin releasing hormone in infective febrile illnesses. J Clin Endocrinol Metab 1977; 44:398-403
11. Van den Berghe G, de Zegher F, Lauwers P: Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol 1994; 41:731-737
12. Van den Berghe G, de Zegher F, Lauwers P: Dopamine suppresses pituitary function in infants and children. Crit Care Med 1994; 22:1747-1753
13. Van den Berghe G, de Zegher F, Lauwers P, et al: Growth hormone secretion in critical illness: Effect of dopamine. J Clin Endocrinol Metab 1994; 79:1141-1146
14. Snyder PJ, Utiger RD: Response to thyrotropin releasing hormone (TRH) in normal man. J Clin Endocrinol Metab 1972; 34:380-385
15. D'Orio V, El Allaf D, Juchmes J, et al: The use of low doses of dopamine in intensive care medicine. Arch Int Physiol Biochim Biophys 1984; 92: S11-S15
16. Goldberg LI: Dopamine - Clinical uses of an endogenous catecholamine. N Engl J Med 1974; 291:707-710
17. Bouillon R, De Moor P: Heterogeneity of human growth hormone in serum. Ann Endocrinol (Paris) 1974; 35:606-613
18. Jackson IMD: Thyrotropin releasing hormone. N Engl J Med 1982; 306: 145-155
19. Larsen PR, Ingbar SH: The thyroid gland. In: Williams Textbook of Endocrinology. Wilson JD, Foster DW (Eds). Philadelphia, WB Saunders, 1992, pp 357-187
20. van der Poll T, Romijn JA, Wiersinga WM, et al: Tumor necrosis factor: A putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab 1990; 71:1567-1572
21. Stouthard JML, van der Poll T, Endert E, et al: Effects of acute and chronic interleukin-6 administration on the thyroid hormone metabolism in humans. J Clin Endocrinol Metab 1994; 79:1342-1346
22. Vanloon GR, Schwarz L, Sole MJ: Plasma dopamine responses to standing and exercises in man. Life Sci 1979; 24:2273-2278
23. Viquerat CE, Dolly P, Swedberg K, et al: Endogenous catecholamine levels in chronic heart failure. Relation to the severity of hemodynamic abnormalities. Am J Med 1985; 78:455-460
24. Van den Berghe G, de Zegher F, Vanhaecke J, et al: Growth hormone as a rescue treatment after heart-lung or double lung transplantation. Endocrinol Metab 1994; 1:187-190
25. Tamai H, Kobayashi N, Fukata S, et al: Paradoxical responses of plasma cortisol, adrenocorticotrope hormone and growth hormone to thyrotropin-releasing hormone and luteinizing hormone-releasing hormone in anorexia nervosa patients. Psychother Psychosom 1986; 46:147-151
26. Maeda K, Kato Y, Ogho S, et al: Growth hormone and prolactin release after injection of thyrotropin releasing hormone in patients with depression. J Clin Endocrinol Metab 1975; 40:501-505
27. Müller EE, Salerno F, Cocchi D, et al: Interaction between the thyrotropin releasing hormone-induced growth hormone rise and dopaminergic drugs: Studies in pathological conditions in the animal and man. Clin Endocrinol 1979; 11:645-656
28. Devins SS, Miller A, Herndon BL, et al: Effects of dopamine on T-cell proliferative responses and serum prolactin concentrations in critically ill patients. Crit Care Med 1992; 20:1644-1649